Addex Financial Statements From 2010 to 2023

ADXN Stock

USD 0.70 0.05 7.69%

Addex Therapeutics financial statements provide useful quarterly and yearly information to potential Addex Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Addex Therapeutics financial statements helps investors assess Addex Therapeutics' valuation, profitability, and current liquidity needs.

We have found seventy-three available fundamental signals for Addex Therapeutics, which can be analyzed and compared to other ratios and to its rivals. Make sure you validate Addex Therapeutics' prevailing fundamentals against the trend between 2010 and 2023 to make sure the company can sustain itself down the road.

Addex Therapeutics Average Assets are very stable at the moment as compared to the past year. Addex Therapeutics reported last year Average Assets of 12.4 Million. As of 1st of June 2023, Average Equity is likely to grow to about 12.3 M, while Earnings Before Interest Taxes and Depreciation Amortization EBITDA are likely to drop (20.7 M).

Check Addex Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Addex main balance sheet or income statement drivers, such as Gross Profit of 2.2 M, Interest Expense of 310.2 K or Operating Expenses of 19.9 M, as well as many exotic indicators such as Asset Turnover of 0.12, Book Value per Share of 0.8 or Current Ratio of 2.45. Addex financial statements analysis is a perfect complement when working with Addex Therapeutics Valuation or Volatility modules. It can also supplement various Addex Therapeutics Technical models . Check out the analysis of Addex Therapeutics Correlation against competitors. To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide.

Addex Therapeutics Revenues

2.16 Million

Addex Therapeutics Balance Sheet

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Trade and Non Trade Receivables

349.2 K

416.9 K

273 K

Pretty Stable

Property Plant and Equipment Net

417.9 K

398.7 K

185.3 K

Slightly volatile

Trade and Non Trade Payables

3.2 M

3 M

1.9 M

Slightly volatile

Liabilities Non Current

89.3 K

87 K

572.7 K

Slightly volatile

Current Liabilities

3.7 M

3.3 M

2.5 M

Slightly volatile

Total Liabilities

4.4 M

3.4 M

3.1 M

Slightly volatile

Investments Non Current

57.7 K

54.4 K

29.2 K

Slightly volatile

Investments Current

3.2 K

14.3 K

Pretty Stable

Investments

70.8 K

57.5 K

44.3 K

Slightly volatile

Shareholders Equity USD

5.4 M

5.3 M

8.8 M

Slightly volatile

Shareholders Equity Attributable to Parent

5 M

4.9 M

8.4 M

Slightly volatile

Deferred Revenue

79.9 K

77.8 K

321.7 K

Slightly volatile

Total Debt USD

436.7 K

401.2 K

548.9 K

Slightly volatile

Debt Non Current

121.3 K

87 K

173.8 K

Pretty Stable

Debt Current

282.7 K

286.1 K

349.7 K

Slightly volatile

Total Debt

404 K

373.1 K

523.5 K

Slightly volatile

Cash and Equivalents USD

7.7 M

7.5 M

11.1 M

Slightly volatile

Cash and Equivalents

7.1 M

7 M

10.5 M

Slightly volatile

Assets Non Current

475.7 K

453.1 K

214.5 K

Slightly volatile

Current Assets

8 M

7.8 M

11.2 M

Slightly volatile

Total Assets

8.5 M

8.3 M

11.4 M

Slightly volatile

Addex Therapeutics Income Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Weighted Average Shares

36.6 M

37.9 M

28.1 M

Slightly volatile

Selling General and Administrative Expense

6.6 M

7.3 M

3 M

Slightly volatile

Research and Development Expense

13.3 M

14.7 M

6.4 M

Slightly volatile

Revenues USD

2.3 M

1.5 M

5 M

Slightly volatile

Revenues

2.2 M

1.4 M

4.8 M

Slightly volatile

Operating Expenses

19.9 M

22 M

9.4 M

Slightly volatile

Interest Expense

310.2 K

313.3 K

152.4 K

Slightly volatile

Gross Profit

2.2 M

1.4 M

4.8 M

Slightly volatile

Addex Therapeutics Cash Flow Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Effect of Exchange Rate Changes on Cash

(211.7 K)

(196.2 K)

(102.2 K)

Slightly volatile

Net Cash Flow from Operations

(16.9 M)

(16.4 M)

(6.1 M)

Slightly volatile

Net Cash Flow Investment Acquisitions and Disposals

3.8 K

3.6 K

(30.8 K)

Slightly volatile

Net Cash Flow from Investing

3.2 K

3 K

(13.5 K)

Slightly volatile

Net Cash Flow from Financing

3.2 M

3.1 M

6.2 M

Pretty Stable

Issuance Purchase of Equity Shares

1.1 M

6 M

Very volatile

Net Cash Flow or Change in Cash and Cash Equivalents

(13.7 M)

(13.3 M)

90.5 K

Pretty Stable

Depreciation Amortization and Accretion

305.3 K

323.1 K

129.5 K

Slightly volatile

Financial Ratios

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Tangible Assets Book Value per Share

1.35

1.312

7.5564

Slightly volatile

Sales per Share

0.25

0.242

1.0966

Slightly volatile

Return on Invested Capital

12.97

14.629

4.7668

Slightly volatile

Price to Sales Ratio

2.67

2.601

12.4066

Slightly volatile

Price to Book Value

0.78

0.753

3.0372

Slightly volatile

Gross Margin

0.89

0.9

0.9853

Slightly volatile

Free Cash Flow per Share

(2.81)

(2.604)

(0.7199)

Slightly volatile

Enterprise Value over EBITDA

0.31

0.281

(2.3771)

Slightly volatile

Debt to Equity Ratio

0.58

0.686

0.9001

Slightly volatile

Current Ratio

2.45

2.385

3.988

Pretty Stable

Book Value per Share

0.8

0.778

6.7446

Slightly volatile

Asset Turnover

0.12

0.115

0.2145

Slightly volatile

Addex Therapeutics Valuation Data

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Working Capital

4.7 M

4.5 M

8.7 M

Slightly volatile

Tangible Asset Value

8.5 M

8.3 M

11.4 M

Slightly volatile

Market Capitalization

4.1 M

4 M

49.4 M

Slightly volatile

Free Cash Flow

(16.9 M)

(16.4 M)

(6.1 M)

Slightly volatile

Enterprise Value

(6.3 M)

(6.1 M)

31.8 M

Slightly volatile

Average Equity

12.3 M

8.2 M

19.3 M

Slightly volatile

Average Assets

16.5 M

12.4 M

22.5 M

Pretty Stable

Addex Fundamental Market Drivers

Cash And Short Term Investments

7 M

Addex Upcoming Events

	17th of August 2023 Upcoming Quarterly Report	View
	30th of June 2023 Next Fiscal Quarter End	View

About Addex Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Addex Therapeutics income statement, its balance sheet, and the statement of cash flows. Addex Therapeutics investors use historical funamental indicators, such as Addex Therapeutics's revenue or net income, to determine how well the company is positioned to perform in the future. Although Addex Therapeutics investors may use each financial statement separately, they are all related. The changes in Addex Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Addex Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Addex Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Addex Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for 2023
Deferred Revenue	77.8 K	79.9 K
Revenues	1.4 M	2.2 M

Be your own money manager

Our tools can tell you how much better you can do entering a position in Addex Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run My Watchlist Analysis Now

My Watchlist Analysis

Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like

All Next

Launch Module

Pair Trading with Addex Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Addex Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Addex Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Addex Stock

+	0.71	EQ	Equillium	Fiscal Quarter End 30th of June 2023	Pair Corr
+	0.71	KA	Kineta Inc	Symbol Change	Pair Corr
+	0.8	YS	YS Biopharma	Buyout Trend	Pair Corr

Moving against Addex Stock

	-	0.48	VBLT	Vascular Biogenics		Fiscal Quarter End 30th of June 2023	Pair Corr
	-	0.44	VECT	VectivBio Holding		Report 19th of July 2023	Pair Corr

The ability to find closely correlated positions to Addex Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Addex Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Addex Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Addex Therapeutics to buy it.

The correlation of Addex Therapeutics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Addex Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Addex Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Addex Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Check out the analysis of Addex Therapeutics Correlation against competitors. To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide. You can also try Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Complementary Tools for Addex Stock analysis

When running Addex Therapeutics' price analysis, check to measure Addex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Addex Therapeutics is operating at the current time. Most of Addex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Addex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Addex Therapeutics' price. Additionally, you may evaluate how the addition of Addex Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account
	Volatility Analysis Get historical volatility and risk analysis based on latest market data
	Risk-Return Analysis View associations between returns expected from investment and the risk you assume
	Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital

Is Addex Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Addex Therapeutics. If investors know Addex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Addex Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.41)

Revenue Per Share

0.192

Quarterly Revenue Growth

0.493

Return On Assets

(0.83)

Return On Equity

(1.90)

The market value of Addex Therapeutics is measured differently than its book value, which is the value of Addex that is recorded on the company's balance sheet. Investors also form their own opinion of Addex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Addex Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Addex Therapeutics' market value can be influenced by many factors that don't directly affect Addex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Addex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Addex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Addex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party. Check out the analysis of Addex Therapeutics Correlation against competitors. To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2023 Macroaxis LLC

Addex Financial Statements From 2010 to 2023

Addex Therapeutics Revenues

2.16 Million

Addex Therapeutics Balance Sheet

Addex Therapeutics Income Statement

Addex Therapeutics Cash Flow Statement

Financial Ratios

Addex Therapeutics Valuation Data

Addex Fundamental Market Drivers

Addex Upcoming Events

About Addex Therapeutics Financial Statements

Be your own money manager

Did you try this?

Run My Watchlist Analysis Now

My Watchlist Analysis

Pair Trading with Addex Therapeutics

Moving together with Addex Stock

Moving against Addex Stock

Complementary Tools for Addex Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY